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Health Authority, Dubai,Background: Comprehensive cardiovascular disease risk factor (CVDRF) screening programs are limited in the
developing world. Simplifying screening can increase its utility.
Objectives: The present study aims to estimate the burden of CVDRF in volunteers and the yield of newly
discovered CVDRF comparing different sites and nationalities using this screening method.
Methods: Voluntary point-of-care CVDRF screening was conducted in 4 shopping malls, 9 health care fa-
cilities, and 3 labor camps in 5 cities in the United Arab Emirates. Follow-up for newly diagnosed diabetes
mellitus, hypertension, and dyslipidemia was made 1 month after screening to inquire about physician
consultation, conﬁrmation of diagnosis, and lifestyle changes.
Results: A total of 4,128 subjects were screened (43% at malls, 36% at health care facilities, and 22% at labor
camps). Subjects were relatively young (38  11 years), predominantly male (75%), and of diverse
nationalities (United Arab Emirates: 7%, other Arabs: 10%, South Asians: 74%, other Asians: 5%, and
other nationalities: 5%). CVDRF were frequent (diabetes mellitus: 32%, hypertension: 31%, dyslipidemia:
69%, current smokers: 21%, obesity: 20%, and central obesity: 24%). Most subjects (85%) had 1
CVDRF, and many (17%) had 3 CVDRF. A new diagnosis of diabetes mellitus, hypertension, or
dyslipidemia was uncovered in 61.5%, with the highest yield (74.0%) in labor camps. At follow-up of
those with new CVDRF, positive lifestyle changes were reported in 60%, but only 33% had consulted a doctor;
of these, diagnosis was conﬁrmed in 63% for diabetes mellitus, 93% for hypertension, and 87% for
dyslipidemia.
Conclusions: In this relatively young and ethnically diverse cohort, CVDRF burden and yield of screening was
high. Screening in these settings is pertinent and can be simpliﬁed.United Arab Emirates;
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CC BY-NC-ND license.The World Health Organization estimated that in
1998, 78% of the burden of noncommunicable diseases
and 85% of cardiovascular disease (CVD) burden arose
from low- and middle-income countries [1]. The mortality
from ischemic heart disease between 1990 and 2020 has
been projected to increase in developing countries by
120% in women and 137% in men [2]. This expected
increase is even greater for the Middle East countries and is
estimated at 146% in women and 174% in men.
Notably, one-half of the deaths attributable to CVD
would occur prematurely in the developing countries
compared with only a quarter in the developed countries
[1]. In fact, myocardial infarction occurred a decade earlier
in the Middle East and South Asia than in Western Europe
and North America in the global case-control INTER-
HEART (INTERHEART: A Global Study of Risk Factors for
Acute Myocardial Infarction) [3] and the regional Gulf
RACE (Registry of Acute Coronary Events) [4]. This has
considerable economic and social implications on the
family and the nation.GLOBAL HEART, VOL. 10, NO. 4, 2015
December 2015: 265-272Primary prevention of cardiovascular disease risk
factors (CVDRF) is a key tool in reducing this epidemic. This
entails early detection, lifestyle change, and achieving
optimal control of CVDRF. Comprehensive screening pro-
grams are required and are an integral part of health care
systems in many developed countries. Such comprehensive
screening programs can be complex and require substantial
health care resources as well as an established health care
infrastructure. Even though there is increasing realization of
the sharply increasing burden of CVD in the developing
countries, systematic screening programs are rare [5]. There
is a need for new models of delivering screening that are
simple and easily accessible to the population.
The DISCOVERY (Dubai Shopping for Cardiovascular
Risk Study) established a simple and opportunistic
screening program in 5 cities in the United Arab Emirates
(UAE) as part of the World Heart Day campaigns (during
September and October 2012). Its point-of-care (POC)
testing methodology rendered it very accessible for this
economically and ethnically diverse population. It is a265
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266unique program, in that it includes all components of the
UAE population. A pilot phase of the study estimated that
around one-third of relatively young and ethnically diverse
mall shoppers in a major city in the UAE (Dubai) had
1modiﬁable CVDRF that was previously undetected [6].
The present study aims to estimate the burden of
CVDRF in volunteers and the yield of newly discovered
CVDRF comparing different sites and nationalities using
this screening method. There have been no national
systematic random sample risk factor surveys in this
population and this study, to some extent, helps ﬁll that
gap. We also assess the impact of the new diagnosis on the
volunteer’s lifestyle and health careeseeking behavior.METHODS
During the World Heart Day celebration of 2012, from the
last week of September to the end of October 2012, a free,
voluntary CVDRF screening program was offered in 5
major cities of the UAE—Dubai, Abu Dhabi, Sharjah,
Fujairah, and Ras al Khaimah. The venues for the
screening included 4 shopping malls, 9 outpatient health
care facilities, and 3 labor camps (LC). This was an
opportunistic sample and was not intended to provide a
population-based cohort. The sampling strategy was based
on convenience for the investigators and for the
participants.
Adults aged 18 years or older were invited to take
part. The study used a single-page, standardized ques-
tionnaire and data form and standardized methodology for
measuring blood pressure (BP), height, weight, waist
circumference, capillary nonfasting total and high-density
lipoprotein (HDL) cholesterol, and capillary hemoglobin
A1c (HbA1c). On-site counseling was delivered by physi-
cians. Arterial BP was measured using a standard method:
the mean of 2 consecutive measurements was recorded
after the subject had rested for 5 min [7]. Blood pressure
was measured using Omron (Kyoto, Japan) upper arm BP
monitor M10-IT with international protocol and British
Hypertension Society protocol clinical validation. Weight
was measured by Omron Body Composition Monitor Bf-
511, a clinical validation and Technischer Überwa-
chungs-Verein-certiﬁed medical wellness product. Waist
circumference was measured, while standing, midway
between the lowest rib and the top of the iliac crest
directly on the skin or close-ﬁtting clothing using a non-
ﬂexible tape measure attached to a spring balance exerting
a force of 75 g [3].
POC machines were used with capillary blood samples.
Total cholesterol and HDL were measured by Cardiocheck
and HbA1c was measured by Clover A1c Glycosylated
Hemoglobin Monitoring System (EuroMedix, Leuven,
Belgium) compliant with DCCT (Diabetes Control and
Complications Trial) reference method and certiﬁed to in-
ternational standards (International Federation of Clinical
Chemistry and National Glycohemoglobin Standardization
Program) for POC testing during screening and monitoringof diabetes [8]. All POC machines were calibrated before
each session.
Major CVDRF were deﬁned as follows: dyslipidemia
was deﬁned as a history of known or treated dyslipidemia
(receiving cholesterol-lowering medication) or a
measured total cholesterol 200 mg/dl or HDL choles-
terol <40 mg/dl [9]. Hypertension was deﬁned as a his-
tory of known and treated hypertension (receiving
antihypertensive medication) or a measured systolic
blood pressure 140 mm Hg or diastolic blood pressure
90 mm Hg [10]. Obesity was deﬁned as a body mass
index of 30.0 kg/m2 using measured height (m) and
weight (kg) [11]. Diabetes mellitus was deﬁned as a his-
tory of known and treated diabetes (receiving anti-
hyperglycemic medication) or a measured HbA1c 6.5%
[12]. Current smoking was deﬁned as using cigarettes or
other tobacco products [13]. Central obesity was deﬁned
as waist circumference of 102 cm in male and 88 cm
in female subjects [14].
At 1-month post-screening, a telephone follow-up call
was made to those who were identiﬁed as having a new
risk factor (mean systolic blood pressure 140 mm Hg
and/or diastolic blood pressure 90 mm Hg, HbA1c
6.5%, and total cholesterol 200 mg/dl). A standardized
list of questions were asked to determine whether they had
contacted their physicians; had their diagnosis conﬁrmed;
and had made dietary, physical activity, or smoking life-
style changes.
Consent was taken for screening and use of data for
research purposes. Ethical approval from the Medical
Research Committee of Dubai Health Authority was ob-
tained (Ref#MRC-07/2012_09).
The medical team supervisors as well as the doctors,
nurses, and other health workers within the team were
given hands-on training on the content of the question-
naire, the standardized methods for BP, height, waist, and
weight measurements, as well as POC measurements of
total and HDL cholesterol and HbA1c. A conﬁrmative test
with the subject’s physician was advised.
Statistical methods
Stata software (version 10, StataCorp LP, College Station,
Texas) was used for all analyses. The prevalence of CVDRF
in the study cohort was estimated using the number of
known and new cases as the numerator and the total
number of study participants without missing information
for that risk factor as the denominator. Comparisons of
prevalence rates were made between recruitment sites and
between nationalities with statistical signiﬁcance at
p <0.05 after adjusting for age and sex.
RESULTS
We screened 4,128 subjects with a mean age  SD of 38 
11 years, of whom 3,105 (75%) were male. Screening was
undertaken at 3 site categories: 1,775 (43%) in 4 malls;
1,486 (36%) in 9 government or private health careGLOBAL HEART, VOL. 10, NO. 4, 2015
December 2015: 265-272
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facilities; and 867 (21%) in 3 LC. The baseline character-
istics according to recruitment site are described in Table 1.
Age was lowest in the LC, where almost all were male
(99.7%) and non-UAE nationals (100%). Current smoking
status was highest in LC at 36% compared with other sites
(15% to 21%), and they also had the lowest body mass
index, HDL cholesterol, and HbA1c levels, as well as mean
10-year Framingham CVD risk scores.
The overall mean 10-year Framingham CVD risk score
in male subjects was 5.5% and it was highest (7.2%) in
UAE nationals.
Prevalence of risk factors and risk burden
The prevalence of CVDRF (self-reported and uncovered)
according to site and nationality are summarized in
Table 2. Of those screened, 3,465 (85%) had 1CVDRF,
and 693 (17%) had 3 CVDRF. Overall, the screenedTABLE 1. Baseline Characteristics According to Recruitment Site
All
(N ¼ 4,128)
Health
(n
Age, yrs 38.4  11.4 40
Male 3,105 (75.4) 9
Nationality
UAE 275 (6.7) 24
Other Arabs 410 (9.9) 15
South Asians 3,042 (73.7) 94
Other Asians 190 (4.6) 3
Others 211 (5.1) 10
Occupation
Professional 1,125 (27.9) 45
Skilled 1,115 (27.7) 24
Nonskilled 861 (21.4) 22
Housewife 435 (10.80) 19
Retired 77 (1.91) 4
Unemployed/others 416 (10.33) 28
Education
1e8 yrs 665 (16.2) 23
9e12 yrs 1,239 (30.2) 48
Trade school/college or university 1,927 (46.96) 67
None/not mentioned 273 (6.65) 7
Current smoking 850 (20.8) 22
BMI 26.6  4.6 27
Waist 89.8  12.5 87
Systolic BP 124.9  16.8 123
Diastolic BP 80.9  11.1 79
Total cholesterol 163.5  37.7 156
HDL cholesterol 42.2  14.2 42
HbA1c 6.5  1.7 6
Framingham CVD 10-year risk score 5.3  7.1 5
Male subjects 5.5  7.3 5
Female subjects 4.7  6.0 4
Values are mean  SD or n (%).
BMI ¼ body mass index; BP ¼ blood pressure; CVD ¼ cardiovascular
UAE ¼ United Arab Emirates.
GLOBAL HEART, VOL. 10, NO. 4, 2015
December 2015: 265-272cohort had a study prevalence of diabetes of 32%, hyper-
tension of 31%, and dyslipidemia of 69%. Body habitus
status of overweight was seen in 42%, obesity in 20%, and
central obesity in 24%. Current smoking was reported
in 21% of the cohort and an additional 7.4% were ex-
smokers. Current smoking was lowest in UAE nationals
at 15% and highest in other Arabs at 27%. Family history
of diabetes and CVD was present in 39% and 29%,
respectively, and was highest among UAE nationals. UAE
nationals also had the highest rates of obesity both by body
mass index and waist circumference.
Uncovered CVD risk factors and screening yield
Table 3 reports newly uncovered risk factors. Of all the
diabetics in the cohort, 677 (52%) were previously un-
aware of their risk factor. Similarly, 558 (44%) of hyper-
tensive and 2,004 (71%) of dyslipidemia subjects were notCare Facility
¼ 1,490)
Malls
(n ¼ 1,784)
Labor Camps
(n ¼ 854) p Value
.2  12.0 40.2  10.9 31.5  8.1 <0.001
76 (65.7) 1,278 (71.8) 851 (99.7) <0.001
<0.001
2 (16.2) 33 (1.9)
9 (10.7) 234 (13.1) 17 (2.0)
9 (63.7) 1,267 (71.0) 826 (96.7)
6 (2.4) 150 (8.4) 4 (0.5)
4 (7.0) 100 (5.6) 7 (0.8)
<0.001
1 (31.2) 646 (36.3) 28 (3.5)
4 (16.9) 503 (28.2) 368 (45.8)
9 (15.89) 260 (14.6) 372 (46.3)
7 (13.63) 238 (13.36)
4 (3.04) 33 (1.85)
0 (19.38) 101 (5.67) 35 (4.35)
<0.001
8 (16.2) 107 (6.0) 320 (37.5)
8 (33.2) 471 (26.4) 280 (32.8)
1 (45.71) 1,169 (65.56) 87 (10.2)
1 (4.83) 36 (2.02) 166 (19.47)
1 (15.1) 320 (18.0) 309 (36.2) <0.001
.3  4.8 27.4  4.3 23.8  3.8 <0.001
.9  15.1 92.2  11.0 87.5  9.8 0.3
.3  17.2 125.6  17.5 125.2  14.3 0.01
.9  11.2 81.6  11.2 80.8  10.5 0.06
.3  38.3 175.2  35.9 151.5  33.4 0.9
.6  16.0 43.7  13.9 38.7  10.2 <0.001
.5  1.8 6.5  1.8 6.1  1.6 <0.001
.7  7.5 6.3  7.6 3.0  4.9 <0.001
.9  7.6 6.5  7.8 3.0  4.9
.9  6.1 5.6  6.5 -
disease; HbA1c ¼ hemoglobin A1c; HDL ¼ high-density lipoprotein;
267
TABLE 2. Prevalence of CVD Risk Factors (Self-Reported and Uncovered) by Recruitment Site and Nationality
Site
p Value*
Nationality
p Value*
All
(N ¼ 4,128)
Health Care Facility
(n ¼ 1,490)
Malls
(n ¼ 1,784)
Labor Camps
(n ¼ 854)
UAE
(n ¼ 275)
Other Arabs
(n ¼ 410)
South Asians
(n ¼ 3,042)
Other Asians
(n ¼ 190)
Other
(n ¼ 211)
Diabetes 1,303 (31.6) 539 (36.2) 619 (34.7) 145 (17.0) <0.001 127 (46.2) 120 (29.3) 965 (31.7) 2 (22.1) 49 (23.2) 0.002
Hypertension 1,261 (30.6) 432 (29.0) 623 (34.9) 206 (24.1) 0.003 83 (30.2) 94 (22.9) 959 (31.5) 4 (39.0) 51 (24.2) <0.001
Dyslipidemia 2,828 (68.5) 1,036 (69.5) 1,218 (68.3) 574 (67.2) <0.001 182 (66.2) 284 (69.3) 2,160 (71.0) 1 1 (53.2) 101 (47.9) <0.001
BMIy <0.001 <0.001
Overweight 1,711 (41.9) 622 (42.5) 838 (47.5) 251 (29.4) 92 (34.3) 170 (41.9) 1,300 (43.1) 6 (40.4) 73 (35.8)
Obese 799 (19.6) 349 (23.9) 404 (22.9) 46 (5.4) 125 (46.6) 166 (40.9) 426 (14.1) 0 (16.0) 52 (25.5)
Central obesityz 927 (24.0) 389 (30.5) 468 (26.8) 70 (8.3) 0.085 115 (55.8) 160 (43.5) 539 (18.5) 1 (27.9) 62 (33.0) <0.001
Smoking 0.067 <0.001
Previous 305 (7.4) 146 (10.0) 131 (7.4) 28 (3.3) 19 (7.2) 35 (8.6) 223 (7.4) 0 (5.3) 18 (8.6)
Current 850 (20.8) 221 (15.1) 320 (18.0) 309 (36.2) 39 (14.7) 111 (27.3) 646 (21.3) 3 (12.2) 31 (14.8)
Family history of DM 1,472 (39.3) 620 (48.0) 739 (43.7) 113 (14.8) <0.001 130 (55.8) 160 (42.4) 1,063 (38.3) 2 (29.2) 67 (36.2) <0.001
Family History of CVD 1,052 (28.7) 417 (34.2) 562 (33.4) 73 (9.5) <0.001 94 (42.7) 114 (30.2) 719 (26.4) 4 (36.6) 61 (34.5) <0.001
Values are n (%).
DM ¼ diabetes mellitus; other abbreviations as in Table 1.
*The p values are adjusted for age and sex.
yOverweight ¼ 25 to 29.9; obese ¼ 30þ.
zWaist: male: 102 cm, female: 88 cm.
TABLE 3. Uncovered Diabetes Mellitus, Hypertension, and Dyslipidemia Compared With Study Prevalence by Recruitment Site and Nationality
Site
p Value
Nationality
p ValueAll
Health Care
Facility Malls Labor Camps UAE Other Arabs South Asians O her Asians Other
Diabetes (new/all) 677/1,303 (51.9) 243/539 (45.1) 325/619 (52.5) 109/145 (75.2) <0.001 49/127 (38.6) 58/120 (48.3) 515/965 (53.4) 3 /42 (73.8) 24/49 (49.0) 0.002
Hypertension
(new/all)
558/1,261 (44.3) 134/432 (31.0) 269/623 (43.2) 155/206 (75.2) 0.003 12/83 (14.5) 23/94 (24.5) 474/959 (49.4) 3 /74 (43.2) 17/51 (33.3) <0.001
Dyslipidemia
(new/all)
2,004/2,828 (70.9) 668/1,036 (64.5) 799/1,218 (65.6) 537/574 (93.6) <0.001 80/182 (44.0) 193/284 (68.0) 1,588/2,160 (73.5) 7 /101 (69.3) 73/101 (72.3) <0.001
Any “new” RF
(new/overall)
2,538/4,128
(61.5)
839/1,490
(56.3)
1,067/1,784 (59.8) 632/854 (74.0) 0.003 112/275 (40.7) 229/410 (55.9) 1,993/3,042 (65.5) 10 /190 (53.7) 87/211 (41.2) 0.058
Values are n/n (%).
RF ¼ risk factor(s); UAE ¼ United Arab Emirates.
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aware of their respective diagnosis prior to screening. The
overall yield of screening as measured by any newly un-
covered CVDRF (diabetes, hypertension, or dyslipidemia)
during screening was 62% and was signiﬁcantly higher
in LC (74%) where 75% of diabetic, 75% of hypertensive,
and 94% of dyslipidemia subjects were unaware of their
diagnoses.
The yield of detecting a new risk factor was higher in
male subjects at 2,031 (65.4%) than in female subjects at
354 (34.8%). In a multivariate model including age, sex,
obesity, and smoking, only age (per 10 years) was nega-
tively associated (odds ratio [OR]: 0.834; 95% conﬁdence
interval [CI]: 0.784 to 0.886; p < 0.001) and male sex was
positively associated (OR: 3.441; 95% CI: 2.930 to 4.042;
p < 0.001) with the detection of a new risk factor at
screening. The yield did not increase when those younger
than 30 years of age were excluded.
Control of known CVDRF
Among those with prior diagnosis of diabetes mellitus, 205
(33%) had HbA1c of <7%, 209 (34%) between 7% and
9%, and 203 (33%) >9%. There was no signiﬁcant
difference between nationalities. Among those previously
diagnosed to have hypertension, 290 (48%) had a BP
<140/90 mm Hg, 211 (35%) between 140/90 and
160/100 mm Hg, whereas 99 (17%) were >160/100 mm
Hg. BP control (BP <140/90 mm Hg) was worse in the
South Asians than in UAE nationals (44% vs. 74%;
p ¼ 0.004). Total cholesterol of <200 mg/dl was recorded
in 613 (75%) of those with previous diagnosis of dyslipi-
demia, and this was signiﬁcantly higher in UAE nationals
than in Other Asians (87% vs. 58%; p ¼ 0.046).
Follow-up of the new CVD risk factors
Table 4 shows the follow-up of new CVDRF by site and
nationality. We were able to contact >80% of subjects with
new diabetes, hypertension, or dyslipidemia. Subsequent
follow-up consultation with a physician had occurred in
approximately one-third of patients. Conﬁrmation of
diagnosis by a physician was established in 63% for dia-
betes, 93% for hypertension, and 87% for dyslipidemia.
Self-reported lifestyle change (general questions regarding
change in food habits, physical activity, and tobacco
cessation) occurred in 56% to 66%.
DISCUSSION
This study describes a simple and accessible screening
methodology delivered where the population is conve-
niently available, that is, at malls, LC, and health care
centers. The subjects are not required to be fasting; they
undergo a short, 1-page questionnaire; basic anthropo-
metric and BP measurements; and POC capillary testing
for HbA1c, total cholesterol, and HDL cholesterol with an
onsite physician for counseling. We screened all comers
including those with pre-existing CVDRF, for 2 major
reasons: 1) they might have other CVDRF beside those thatGLOBAL HEART, VOL. 10, NO. 4, 2015 269
December 2015: 265-272
j gSCIENCE
270were known to them, for example, looking for diabetes in
those with hypertension; and 2) they would get some idea
of control of their known CVDRF. So this program may
not be a “pure” screening program, but is a useful method
of increasing CVDRF awareness and control. This is
particularly relevant where health care systems are patchy
and do not cover the whole population.
We found a high burden of CVDRF irrespective of site
of screening and nationality, although there was consid-
erable heterogeneity. There was also a high screening yield
in that 1 new CVDRF was uncovered in one-half of all
subjects, regardless of nationality or site. This was highest
in the LC (74%) where 3 in 4 of diabetic or hypertensive
subjects and nearly 9 in 10 dyslipidemics were not aware of
their risk factor. Notably, around 2 in 3 of subjects with a
newly discovered risk factor at screening did not seek
medical attention within 1 month of follow-up, but among
those that did, the CVDRF was conﬁrmed in the majority.
Younger age and male sex increased the chance of
having a new risk factor detected. This suggests that it
would not be effective to limit screening to older adults as
is seen in some governmental programs for example in
United Kingdom [15]. Although the yield of screening was
higher in male subjects, it was still substantial (35%) in
female subjects. In addition, obesity and smoking status
did not alter the odds of detecting another new risk factor
at screening, hence limiting screening to obese subjects and
smokers is not beneﬁcial either.
The mean overall Framingham 10-year risk score for
CVD events was 5.3%, which is comparable to 4.8% in the
comprehensive Weqaya study of the Abu Dhabi national
population [16]. This may be misleadingly low due to the
heavy reliance of the Framingham risk score on age and the
fact that both the Weqaya and this cohort are relatively
young. In addition, the Framingham risk score is known to
underestimate risk in populations where the cardiovascular
risk burden or prevalence of diabetes is high, such as in the
UAE [17]. The high CVDRF burden in this cohort is shown
by the fact that 85% of our relatively young cohort had
1CVDRF. This could be compared with 1 risk factor in
80% in men and 71% of women in the U.S. Hispanic and
Latino adult population in the HCHS/SOL (Hispanic
Community Health Study/Study of Latinos) using similar
criteria [18]. Our estimates are also consistent with the
recently reported Africa Middle East Cardiovascular
Epidemiological Study, where the vast majority of subjects
(92%) had 1modiﬁable cardiovascular risk factor, and
approximately one-half (53%) had 3, a ﬁnding that was
observed in both sexes and across urban and rural centers
[19]. This further strengthens the justiﬁcation for system-
atic CVD screening in this population.
Screening can be resource-intensive and difﬁcult to
administer; rates as low as 32% are achieved in some
Western screening programs [20]. Screening methods that
are more accessible and rapidly deployed such as POC
testing can increase the uptake and reduce the cost of
screening. POC testing has been debated vigorously, but itsuse has been escalating with increasing reports of its reli-
ability, cost-effectiveness and its ability to increase patient
satisfaction [21,22]. Other means of simplifying screening
include the use of touch screens in general practice
reception areas in Australia [23] and training and equip-
ping lay people to carry out screening in people’s homes in
Kerala, India [24]. The simple method and high accessi-
bility used in the current study is especially beneﬁcial in
populations where the burden of CVRF is high.
The health careeseeking and lifestyle behaviors post-
screening are also important in terms of inﬂuencing
outcomes. Ideally individuals diagnosed with new risk
factors would visit a physician to conﬁrm the diagnosis
and control the risk factor through lifestyle changes, and if
required, by medication. Only with control of the risk
factor would the risk of CVD events decrease. In this study,
at follow-up, approximately 2 in 3 individuals reported to
have changed their lifestyle, but only 1 in 3 had consulted a
physician. Whereas the self-reported change in lifestyle
may reﬂect a change in knowledge and attitude, it is not
clear if lifestyle behavior had also improved. Also the very
low rate of consulting with their physician is clearly
unacceptable if we want to control CVDRF. Health
careeseeking behavior of asymptomatic individuals in
particular is a complex mix of social, psychological,
cultural, and biomedical factors [25]. To make screening a
more effective tool, however, further studies are needed to
understand this and to increase the link to health care
systems. Currently in UAE, access to care and insurance
coverage for non-nationals is slowly evolving but many
non-nationals remain uninsured or underinsured.
Whereas the diagnosis of hypertension and dyslipide-
mia were conﬁrmed in about 90% of subjects during
consultation with their physicians, the diagnosis of diabetes
was conﬁrmed in only 62%. This could be because of
the different tests that the physicians could have used
for conﬁrmation (fasting glucose, post-prandial glucose,
oral glucose tolerance test, or HbA1c); on the other hand, it
could also be due to the inaccuracies from the use of POC
method for HbA1c.
Among subjects with a previous diagnosis of risk
factors, diabetes was uncontrolled in 2 of 3, hypertension 1
in 2, and hypercholesterolemia in 1 in 4. The poor control
was universal for diabetes but was signiﬁcantly worse
among South Asians for hypertension as well as hyper-
cholesterolemia. The differences could be due to access to
and cost of health care, but this needs to be further
investigated.Strengths and limitations
This study looked at the usefulness of screening for CVDRF
in a multiethnic society. The strength of this study is the
real-life setting, the inclusion of all components of society,
and the large number of subjects screened in several cities/
settings in the UAE. As far as we know, this is the largest
study looking at screening in a multiethnic population inGLOBAL HEART, VOL. 10, NO. 4, 2015
December 2015: 265-272
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the UAE. The study also included different socioeconomic
categories, including the migrants and unskilled workers.
However, there were several limitations of the study.
Female subjects represented only 25% of the cohort, which
mirrors the low female proportion of the adult population
demographics, and is consistent with the 2010 population
estimate from the National Bureau of Statistics of UAE [26].
Also, this was a convenience sample; therefore, the results
are not generalizable to the UAE population as would
be the results of a population-based, random sampling
method. However, whereas this study cannot report
standardized population prevalence rates, it provides an
indication of the relative CVDRF burden between nation-
alities and segments of society.
A possible limitation was that we used POC testing for
total cholesterol, HDL, and HbA1c. Although there has
been some doubt of their accuracy, especially for HbA1c,
this method is advantageous due to the increased accessi-
bility and faster turnaround, with real-time feedback of
results [21]. There has been increasing evidence of its
accuracy and increasing use in primary health care setting
for screening as well as monitoring [27]. For instance, the
Ontario Health Technology Assessment Series 2014 re-
ported that pooled results from 5 studies showed a positive
correlation between POC HbA1c testing and laboratory
HbA1c measurement (correlation coefﬁcient: 0.967, 95%
CI: 0.960 to 0.973) [28]. In our study, the staff using the
POC machines received training and performed quality
control to reduce the error rate.
Although this study followed up at least 1 month after
screening, more details of the lifestyle changes and whether
it was sustained, would have been desirable as would
further details about their failure to seek help once the risk
factor was identiﬁed. For instance, the insurance status of
the subjects was unfortunately not collected. Further
research should look at these aspects as well as the cost and
clinical effectiveness of such a screening program.
CONCLUSIONS
In this relatively young and ethnically diverse cohort, the
CVDRF burden is high, with 85% subjects having
1CVDRF. The high CVDRF burden is present at all
screening sites and among all nationalities. The yield from
screening was high irrespective of site or nationality with
between 40% and 70% of the CVDRF newly uncovered at
screening. The yield was higher in male subjects (65%) and
in LC subjects (74%). However it was not reduced when
those younger than 30 years were excluded and was also
substantial in female subjects (35%). This study suggests
that screening is beneﬁcial in all adults in the UAE.
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